Stay updated with breaking news from Jin Yang Gon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HLB has vowed to seek approval with the U.S. Food and Drug Administration (FDA) again quickly for its liver cancer drug Rivoceranib following the FDA's rejection on Friday, but it is unclear whether the drug will be approved next time, ...
HLB, awaiting new drug approval in the U.S. for its liver cancer drug Rivoceranib, said Tuesday its liver cancer treatment improved the conditions of patients who were deemed inoperable.
HLB, a local pharmaceutical firm, said it has received a letter of notification from the U.S. Drug Administration (FDA) for its liver cancer treatment drug Rivoceranib to undergo New Drug Application (NDA) filing acceptance, according to the firm, Tuesday.
HLB to supply Vietnam's Nanocovax COVID-19 vaccine